Published in final edited form as:

Pharmacol Biochem Behav. 2012 February ; 100(4): 801–810. doi:10.1016/j.pbb.2011.04.015.

Glutamatergic medications for the treatment of drug and behavioral addictions

M. Foster Olive^{1,*}, Richard M. Clewa¹, Peter W. Kalivas², and Robert J. Malcolm³

¹Department of Psychology, Arizona State University, Tempe, AZ 85287

²Department of Neurosciences, Medical University of South Carolina, Charleston, SC 29425 USA

³Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425 USA

Abstract

Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, D-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.

Keywords

drug addiction; substance abuse; behavioral addiction; pathological gambling; pharmacological therapy; glutamate

1. Introduction

Drug addiction, defined by the American Psychiatric Association as *substance dependence* (American Psychiatric Association, 2002), has numerous maladaptive psychological and behavioral manifestations including: loss of control over drug intake, taking drugs in greater quantities than intended, repeated unsuccessful attempts at quitting or reducing drug use, continued drug use despite negative consequences, and the emergence of drug-specific symptoms of tolerance and/or withdrawal. In addition to numerous intangible humanistic

© 2011 Elsevier Inc. All rights reserved.

*Corresponding author: M. Foster Olive, Ph.D., Department of Psychology, 950 S. McAllister Avenue, PO Box 871104, Tempe, AZ 85287 USA, Phone: 480-727-9557, Fax: 480-965-7598, foster.olive@asu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

factors such as the disruption of families and interpersonal relationships, social dysfunction, and loss of life, the socioeconomic burden that drug addiction places on society is enormous (Cartwright, 2008; Gilson and Kreis, 2009; Malliarakis and Lucey, 2007; Rehm *et al.*, 2009; Spanagel, 2009; Thavorncharoensap *et al.*, 2009). In recent years it has become evident that the neural substrates underlying addiction to drugs of abuse overlap considerably with those of non-drug “behavioral” addictions (i.e., pathological gambling, pornography/internet addiction, etc.) (Grant *et al.*, 2010a).

To date, medications that have been developed to aid in the treatment of addictive disorders have shown only moderate success. Known barriers that compromise the efficacy of medication-based approaches to treatment to addiction disorders include poor medication compliance, adverse side effects, safety issues, variable medication responses within treatment groups, poor integration of medication management into psychosocial or cognitive-behavioral therapies, inaccessibility to medications or adequate health care, and relapse following discontinuation of the therapeutic medication (Koob *et al.*, 2009; Montoya and Vocci, 2008; O'Brien, 2008; Ross and Peselow, 2009; Zahm, 2010). While numerous medications of various classes that have been approved for other medical conditions are currently being investigated as potential aids in the treatment of addictive disorders, the only medications approved specifically for the treatment thus far in the United States are varenicline, bupropion, and nicotine replacement therapies for smoking cessation, long-acting opioids (i.e., methadone or buprenorphine) for opiate dependence, and disulfiram, naltrexone, and acamprosate for alcohol dependence. No medications to aid in the treatment of addiction to cocaine, methamphetamine, or marijuana are currently approved, nor are any approved for the treatment of behavioral addictions.

The purpose of the present review is to provide a summary of the pharmacological mechanisms of action and general clinical efficacy of medications acting on glutamatergic transmission in the treatment of addictive disorders. These medications include acamprosate, N-acetylcysteine, D-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. It should be noted that many of these medications have mechanisms of action that include multiple neurotransmitter systems, and perhaps with the exception D-cycloserine, none are known to selectively target glutamatergic transmission or specific glutamate receptors. However, there is a strong body of preclinical evidence arising from over two decades of animal studies suggesting a critical role for glutamate transmission and glutamate receptors in drug reward, reinforcement, and relapse (Bird and Lawrence, 2009; Bowers *et al.*, 2010; Gass and Olive, 2008; Kalivas *et al.*, 2009; Moussawi and Kalivas, 2010; Olive, 2009, 2010; Reissner and Kalivas, 2010; Tzschentke and Schmidt, 2003; Uys and LaLumiere, 2008). For an overview of glutamatergic transmission and glutamate receptors, the reader is referred to the review by Sanacora in the current issue (*publisher – please insert correct page numbers here*). In addition, the small but growing body of literature on the use of these medications to treat behavioral addictions such as compulsive gambling, and studies on this topic will also be reviewed.

2. Glutamatergic medications for the treatment of substance use disorders

2.1. Acamprosate

2.1.1. Mechanism of Action—Acamprosate (calcium acetylhomotaurine) is derived from homotaurine, a nonspecific γ -aminobutyric acid (GABA) agonist. The molecule is N-acetylated to facilitate penetration across the blood-brain barrier, and is formulated as a calcium salt to increase absorption of the compound from the gastrointestinal tract. Despite these chemical modifications, its overall bioavailability remains poor (i.e., <20%) and requires doses in the range of 2–3 grams per day to demonstrate efficacy. Many pharmacological mechanisms of action of acamprosate have been proposed, but the first

studies suggesting that acamprosate exerts its actions through glutamatergic mechanisms were reported by Zeise and colleagues (Zeise *et al.*, 1990, 1993). These investigators showed that acamprosate reduced the excitation of neuronal firing evoked by iontophoretic application of L-glutamate onto cortical neurons *in vivo*, and inhibited excitatory postsynaptic potentials (EPSPs) evoked by glutamate and N-methyl-D-aspartate (NMDA). Additional evidence for a NMDA antagonist-like mechanism of action of acamprosate came from studies demonstrating that this compound antagonizes NMDA-evoked excitatory postsynaptic currents (EPSCs) in hippocampal neurons (Rammes *et al.*, 2001) and up-regulates NMDA receptor subunit expression in a similar fashion to that observed following treatment with the non-competitive NMDA antagonist MK-801 (Putzke *et al.*, 1996; Rammes *et al.*, 2001). However, some investigators have found no effect of acamprosate on NMDA-mediated synaptic transmission in the CA1 region of the hippocampus (Popp and Lovinger, 2000), while others have found that acamprosate actually potentiates NMDA receptor function in the CA1 region of the hippocampus (Madamba *et al.*, 1996) and in the nucleus accumbens (Berton *et al.*, 1998). Despite these inconsistent electrophysiological findings, binding studies have confirmed an interaction of acamprosate with the spermidine-, glutamate- and/or MK-801-sensitive binding site of the NMDA receptor (al Qatari *et al.*, 1998; Harris *et al.*, 2002; Naassila *et al.*, 1998), and as such acamprosate is often referred to nonspecifically as an “NMDA modulator” (Figure 1). Although the precise molecular target(s) of acamprosate are still not firmly established (Kiefer and Mann, 2010; Reilly *et al.*, 2008), most current theories posit that acamprosate restores the imbalances between excitatory and inhibitory amino acid neurotransmission that result from chronic alcohol consumption (De Witte *et al.*, 2005; Kiefer and Mann, 2010; Spanagel *et al.*, 2005; Umhau *et al.*, 2010).

2.1.2. Clinical Efficacy—The first demonstration of the clinical efficacy of acamprosate in reducing the incidence of relapse in alcoholics was published in the mid-1980's (Lhuintre *et al.*, 1985). Over the years, acamprosate has demonstrated effect sizes ranging from small to moderate in reducing overall alcohol consumption, subjective measures of alcohol craving, and promoting abstinence, as reviewed in recent meta-analyses (Kennedy *et al.*, 2010; Kiefer and Mann, 2010; Kranzler and Gage, 2008; Mann *et al.*, 2008; Mason and Heyser, 2010a, b; Rosner *et al.*, 2010; Snyder and Bowers, 2008). Due to its poor oral bioavailability, large doses of acamprosate (typically in the 2–3 g per day range) are needed in order to observe efficacy. However, a recent large multi-center study of over 1200 alcohol-dependent patients (known as the Combined Medications and Behavioral Interventions, or “COMBINE” study) found that acamprosate was no more effective than placebo in reducing the incidence of relapse in a medically managed setting (Anton *et al.*, 2006). Other recent studies have also demonstrated a lack of efficacy of acamprosate in reducing alcohol consumption or craving, or promoting abstinence (Donovan *et al.*, 2008; Laaksonen *et al.*, 2008; Morley *et al.*, 2006; Richardson *et al.*, 2008). The reasons for these negative findings, especially in light of numerous previous positive findings (summarized in the meta-analyses cited above), are still being debated. Some investigators have suggested that a significant “placebo effect” in the COMBINE study might have masked any beneficial effects of acamprosate (Weiss *et al.*, 2008), and that improvements in nondrinking related outcomes measures such as quality of life were in fact superior in acamprosate- versus placebo-treated patients in the COMBINE study (LoCastro *et al.*, 2009). Others have suggested that initiation of acamprosate treatment following detoxification produces reductions in alcohol craving as opposed to when given during active alcohol consumption (Kampman *et al.*, 2009), as was done in the COMBINE study. The requirement for three doses per day may be a compliance barrier for some patients. Decreased motivation to initiate treatment amongst depressed as compared to non-depressed alcoholics significantly affects treatment compliance in acamprosate-treated patients (Lejoyeux and Leher, 2011).

Finally, other motivational factors such as having a treatment goal of complete abstinence as opposed to moderate drinking appear to have beneficial effects in patients treated with acamprosate as compared with placebo (Mason *et al.*, 2006; Mason and Leher, 2010). It is likely that, as with any psychotropic medication, specific subsets of patients may respond better to acamprosate than others. Additional research is clearly needed to determine precisely what these beneficial motivational, methodological, outcome measure, or perhaps genetic factors are in order to identify alcoholics that are most likely to exhibit a positive response to acamprosate.

Regarding the utility of acamprosate in treating addiction to other drugs of abuse or behavioral addictions such as pathological gambling, large-scale studies are non-existent, and the few studies that have been published have reported mixed results. For example, a recent case report supported the potential utility of acamprosate in treating pathological gambling (Raj, 2010). On the other hand, Kampman and colleagues recently reported that in a double-blind placebo-controlled trial of 60 cocaine-dependent patients, acamprosate showed no beneficial effects on cocaine use, craving, or withdrawal symptoms as compared to patients receiving placebo (Kampman *et al.*, 2011). These latter findings are particularly disappointing since several rodent studies have shown that acamprosate attenuates the conditioned rewarding effects of cocaine as well as drug- and cue-primed reinstatement of cocaine-seeking behavior (Bowers *et al.*, 2007; McGeehan and Olive, 2003, 2006). However, given the small sample size and high dropout rate of the study by Kampman and colleagues, the possibility remains that acamprosate may be beneficial in the treatment of cocaine addiction in a as of yet undefined subset of cocaine-dependent individuals.

2.2. N-acetylcysteine (NAC)

2.2.1. Mechanism of Action—NAC is an N-acetylated derivative of the naturally occurring amino acid cysteine. Once inside major internal organs including the brain, NAC is deacetylated to form free cysteine, and homodimerization of two cysteine molecules via a disulfide bond results in the formation of cystine. Thus, NAC is considered a cystine pro-drug that binds to the cystine-glutamate exchanger (often referred to as system xc-) and promotes the synthesis of glutathione (Baker *et al.*, 2002; McBean, 2002). Through this mechanism NAC has proven clinical efficacy as a mucolytic agent and in the treatment of acetaminophen overdose. However, in addition to promoting glutathione synthesis, system xc- is an antiporter protein that transports extracellular cystine into glial cells and intracellular glutamate from inside glia into the extracellular environment. The resulting effect of NAC is an elevation of extracellular glutamate levels, which are reduced during protracted cocaine withdrawal (Baker *et al.*, 2002, 2003; Kau *et al.*, 2008; Madayag *et al.*, 2007; Melendez *et al.*, 2005; Moran *et al.*, 2005). This “normalization” of extracellular glutamate levels restores glutamatergic tone on presynaptic release-regulating group II metabotropic glutamate receptors (mGluR2/3, Moran *et al.*, 2005; see Figure 1) and prevents the ability of a subsequent cocaine challenge to increase extracellular glutamate levels in the nucleus accumbens. The end result is an inhibition of the ability of acute cocaine exposure to reinstate cocaine-seeking behavior (Amen *et al.*, 2011; Baker *et al.*, 2003; Kau *et al.*, 2008; Madayag *et al.*, 2007; Moran *et al.*, 2005; Moussawi *et al.*, 2009).

2.2.2. Clinical Efficacy—Based on these findings from animal studies, several studies on the efficacy of NAC to reduce cocaine use, craving, withdrawal symptoms, and relapse in human cocaine addicts have recently been published. In a small safety and tolerability study (n=13 subjects), it was demonstrated that NAC (1200 mg/day for two days) was well-tolerated by cocaine addicts and produced slight trends in reductions in self-reports of cocaine use, craving and withdrawal symptoms (LaRowe *et al.*, 2006). Small follow-up studies (n=15–23 subjects) have confirmed that similar doses of NAC are well-tolerated by

cocaine addicts and actually produce significant reductions in cocaine use and craving in treatment-seeking outpatient cocaine-dependent individuals (Amen *et al.*, 2011; LaRowe *et al.*, 2007; Mardikian *et al.*, 2007). Importantly, however, a recent pilot study showed that NAC does not reduce subjective feelings of a cocaine “high” or “rush” following exposure to video of cocaine-associated cues, but does attenuate craving evoked by acute IV cocaine exposure (Amen *et al.*, 2011). While these latter results may appear to be in disagreement with those of LaRowe, Mardikian, and colleagues, who found reductive effects of NAC on cue-evoked cocaine craving, the extremely small sample size of the study by Amen and colleagues (n=4 subjects) may limit its interpretability. Regardless, these preliminary results provide encouraging data that NAC may be of potential use in the treatment of cocaine addiction, and additional multi-center clinical trials are needed to confirm these results on a larger scale.

With regards to other drugs of abuse, a recent small clinical trial (n=29 subjects) investigated the potential efficacy of NAC in aiding in smoking cessation (Knackstedt *et al.*, 2009). The results of this study showed that NAC treatment (2400 mg/day) reduces the number of cigarettes smoked relative to the number of cigarettes smoked by subjects receiving placebo, but NAC treatment did not reduce plasma carbon monoxide levels, nicotine withdrawal symptoms, or nicotine craving. Another small pilot study (n=24 subjects) demonstrated that NAC reduced marijuana use and craving in marijuana-dependent young adults aged 18–21 compared to placebo (Gray *et al.*, 2010). As for non-drug addictions, a small clinical trial (n=23 subjects) showed that NAC (mean effective dose 1477 mg/day) lowered scores on the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling [PG-YBOCS] (Grant *et al.*, 2007), and it has been shown to be effective in reducing compulsive nail-biting associated with bipolar disorder in three patients (Berk *et al.*, 2009). Finally, NAC was also shown to suppress hair-pulling in a double-blind study of 50 patients with trichotillomania (Grant *et al.*, 2009).

Although all of the aforementioned clinical studies are preliminary and utilized relatively small sample sizes, the seemingly consistent anti-addictive properties of NAC provide compelling evidence that this medication, as well as other compounds that restore glutamate homeostasis (Knackstedt *et al.*, 2010; Sari *et al.*, 2009), may potentially prove to be effective pharmacotherapeutic aids in the treatment of drug and behavioral addictions.

2.3. D-cycloserine (DCS)

2.3.1. Mechanism of Action—DCS (D-4-amino-3-isoxazolidone) is a derivative of the naturally occurring amino acid serine. It acts as co-agonist at the glycine-binding site on the NR1 subunit of the NMDA receptor, which is present in all NMDA receptors in the central nervous system. DCS is insufficient to activate NMDA receptors on its own, and requires the presence of glutamate binding to the receptor in order to exert its effects. Activation of the glycine binding site by DCS enhances NMDA functioning by increasing calcium influx through these receptors without causing neurotoxicity (Sheinin *et al.*, 2001; see Figure 1).

2.3.2. Clinical Efficacy—As a result of its ability to enhance NMDA receptor function, DCS is believed to facilitate synaptic plasticity and certain forms of learning, including Pavlovian associative learning and extinction learning, and as such it has been reported to successfully facilitate the extinction of fear responses in anxiety disorder patients during cue exposure therapy in numerous clinical studies (reviewed in Davis *et al.*, 2006; Myers *et al.*, 2011; Myers and Davis, 2007). With regards to addiction, animal studies have shown DCS facilitates the extinction of a cocaine-induced conditioned place preference (CPP) (Botreau *et al.*, 2006; Thanos *et al.*, 2009), reduces reacquisition of cocaine self-administration by enhancing extinction learning (Nic Dhonnchadha *et al.*, 2010), and also attenuates the

reinstatement of cocaine-seeking in a context-independent manner (Torregrossa *et al.*, 2010). However, only a few clinical studies on the effects of DCS on addictive behaviors have been conducted thus far.

Santa Ana and colleagues (Santa Ana *et al.*, 2009) recently reported that in 12 nicotine-dependent cigarette smokers undergoing cue exposure therapy, administration of DCS (50 mg) significantly attenuated physiological (i.e., skin conductance) responses as well as subjective urge-to-smoke ratings in response to presentation of smoking-associated cues as compared to placebo treated subjects ($n=13$). DCS treated subjects also demonstrated reduced expired carbon monoxide levels at a follow-up assessment one week later, although no effects on general smoking behavior was found. These preliminary findings suggest that DCS may be beneficial in augmenting the effects of cue exposure therapy during attempts at cessation of cigarette smoking. On the contrary, however, another recent study showed that the same dose of DCS actually produced a trend towards increases in subjective reports of cocaine craving in 5 cocaine-dependent individuals (Price *et al.*, 2009). The timing of DCS administration in treatment-seeking patients may be of relevance for these apparent discordant findings. Along these lines, it is worthy to note that a recent animal study showed that infusions of DCS into the basolateral amygdala actually potentiated the reconsolidation of cocaine-associated memories in cocaine self-administering rats (Lee *et al.*, 2009). Clearly more studies are needed to evaluate the possibility that DCS may actually enhance, rather than facilitate the extinction of, the incentive salience of cocaine-associated cues. In addition, studies need to be conducted to determine if DCS enhances the efficacy of cue exposure therapy in humans addicted to drugs of abuse other than cocaine or nicotine, as are studies on the effects of DCS on non-drug addictions.

2.4. Gabapentin

2.4.1. Mechanism of Action—Gabapentin is an anticonvulsant medication that has a general inhibitory effect on neuronal transmission by inhibiting presynaptic voltage-gated Na^+ and Ca^{2+} channels (Dickenson and Ghandehari, 2007; Landmark, 2007; Rogawski and Loscher, 2004). As a result, gabapentin inhibits the release of various neurotransmitters, including glutamate, as illustrated in Figure 1 (Coderre *et al.*, 2007; Cunningham *et al.*, 2004; Dooley *et al.*, 2000; Fink *et al.*, 2000; Maneuf *et al.*, 2004; Maneuf and McKnight, 2001; Shimoyama *et al.*, 2000).

2.4.2. Clinical Efficacy—Numerous studies have shown that gabapentin is efficacious in alleviating the somatic symptoms of alcohol withdrawal (Bonnet *et al.*, 1999; Bozikas *et al.*, 2002; Mariani *et al.*, 2006; Martinez-Raga *et al.*, 2004; Myrick *et al.*, 1998; Rustembegovic *et al.*, 2004; Voris *et al.*, 2003), which often presents with moderate to severe CNS hyperexcitability and convulsions. Gabapentin has also been shown to be superior to the benzodiazepine lorazepam in reducing sleep disturbances associated with alcohol withdrawal (Malcolm *et al.*, 2007). Yet to date, clinical studies on the therapeutic efficacy of gabapentin in reducing drug use, craving, or relapse have yielded mixed results. Several studies have demonstrated that gabapentin (with dose ranges of 600–1200 mg/day) does not reduce the use of cocaine in addicted individuals (Bisaga *et al.*, 2006; Gonzalez *et al.*, 2007), while other studies have shown that gabapentin indeed decreases active cocaine use and craving (Berger *et al.*, 2005; Myrick *et al.*, 2001; Raby, 2000; Raby and Coomaraswamy, 2004), perhaps by attenuating the discriminative stimulus effects of cocaine (Haney *et al.*, 2005). Recent studies have shown that gabapentin (600–1500 mg/day) reduces craving for and use of alcohol (Furieri and Nakamura-Palacios, 2007; Mason *et al.*, 2009; Myrick *et al.*, 2009), and prolongs abstinence from alcohol use in alcohol-dependent subjects (Brower *et al.*, 2008). However, other investigators have shown no effects of similar doses of gabapentin on alcohol craving (Bisaga and Evans, 2006; Myrick *et al.*, 2007). In addition, it

has been reported that gabapentin does not reduce methamphetamine use (Heinzerling *et al.*, 2006), has limited effects on promoting abstinence from smoking (White *et al.*, 2005), and does not ameliorate subjective withdrawal symptoms in opiate-dependent subjects (Kheirabadi *et al.*, 2008). Taken together, these data suggest that gabapentin is effective for the treatment of alcohol withdrawal symptoms and may have some efficacy for reducing craving for alcohol or cocaine (though not all studies support this notion), but this medication is not likely to have any efficacy in reducing addiction to cigarettes, methamphetamine, or alleviating opiate withdrawal symptoms. To our knowledge, gabapentin has not been tested for efficacy in the treatment of behavioral addictions.

2.5. Lamotrigine

2.5.1. Mechanism of Action—Similar to gabapentin, lamotrigine is an anticonvulsant that inhibits presynaptic voltage-gated Na⁺ and Ca²⁺ channels (Dickenson and Ghandehari, 2007; Landmark, 2007; Rogawski and Loscher, 2004), thereby inhibiting the release of various neurotransmitters, including glutamate (see Figure 1; Ahmad *et al.*, 2004; Cunningham and Jones, 2000; Leach *et al.*, 1986; Lees and Leach, 1993; Lingamaneni and Hemmings, 1999; Sitges *et al.*, 2007; Teoh *et al.*, 1995; Waldmeier *et al.*, 1995, 1996; Wang *et al.*, 2001). Lamotrigine carries an uncommon but serious risk of causing a severe skin rash, known as Stevens-Johnson Syndrome. The risk of occurrence of this side effect can be significantly lowered by gradual dose titration, usually starting at a dose of 25 mg/day and tapering up weekly to doses in the range of 200–300 mg/day.

2.5.2. Clinical Efficacy—Like gabapentin, lamotrigine inhibits the somatic signs of alcohol withdrawal (Krupitsky *et al.*, 2007b). Recent clinical studies show that lamotrigine also appears to exhibit efficacy in reducing craving for and use of cocaine (Berger *et al.*, 2005; Brown *et al.*, 2003, 2006; Margolin *et al.*, 1998; Pavlovic, 2011), although it appears to leave the subjective effects of cocaine unaltered (Winther *et al.*, 2000). Similar reductive effects of lamotrigine on craving for alcohol (Rubio *et al.*, 2006) and abused inhalants (Shen, 2006) have been reported. These findings suggest that lamotrigine may be of clinical benefit in the treatment of addiction to cocaine, alcohol or abused inhalants. Studies on the potential efficacy of lamotrigine in the treatment of behavioral addictions or addictions to opiates, nicotine, or psychostimulants such as methamphetamine are lacking.

2.6. Memantine

2.6.1. Mechanism of Action—Memantine is a noncompetitive antagonist at the NMDA receptor (Figure 1) and is used primarily for the treatment of cognitive decline in Alzheimer's disease. In addition to its antagonist actions at NMDA receptors, memantine also blocks the serotonin type 3 receptor (5-HT₃) as well as nicotinic acetylcholine receptors. Although some abuse substances such as phencyclidine, ketamine, dextromethorphan or alcohol have antagonist properties at the NMDA receptor, memantine is one of the few NMDA receptor antagonists that is generally well-tolerated by humans and does not appear to carry an abuse potential (Vosburg *et al.*, 2005).

2.6.2. Clinical Efficacy—In addition to being efficacious at reducing withdrawal symptoms in detoxifying alcoholics (Krupitsky *et al.*, 2007b) and opiate addicts (Bisaga *et al.*, 2001), memantine (typical doses in the 30–60 mg/day range) has been reported to be superior to placebo in attenuating on-going drinking and/or craving for alcohol in alcoholic subjects (Arias *et al.*, 2007; Bisaga and Evans, 2004; Krupitsky *et al.*, 2007a). This amelioration of craving for alcohol may be a result of the alcohol-like subjective effects of memantine (Bisaga and Evans, 2004; Krupitsky *et al.*, 2007a). However, a larger placebo-controlled study indicated that memantine does not reduce on-going drinking behavior in alcohol-dependent patients (Evans *et al.*, 2007). Memantine has been reported to decrease

the subjective effects of cigarette smoking (Jackson *et al.*, 2009) and intravenous heroin (Comer and Sullivan, 2007); however, particularly at higher doses, memantine can increase the subjective and cardiovascular effects of cocaine (Collins *et al.*, 1998, 2007). Collectively, these data suggest that memantine may be of potential use in the detoxification of alcohol- or opiate-dependent patients, and perhaps as a pharmacological adjunct for the treatment of alcoholism. However, its potential efficacy for treating addiction to other drugs of abuse remains unknown, and it appears that it may be contraindicated for treating cocaine addiction. Nonetheless, a recent open label pilot study showed that memantine decreased PG-YBOCS scores and time spent gambling in 29 pathological gamblers (Grant *et al.*, 2010b), suggesting that memantine may be of potential use in the treatment of behavioral addictions such as pathological gambling.

2.7. Modafinil

2.7.1. Mechanism of Action—Modafinil is a CNS stimulant originally designed to enhance wakefulness and vigilance in the treatment of narcolepsy and excessive daytime sleepiness caused by sleep apnea or shiftwork. Modafinil is sometimes prescribed as an off-label treatment for attention-deficit/hyperactivity disorder. Although its neuropharmacological mechanisms of action are not yet fully understood, modafinil does not appear to act as a monoamine releaser as is the case for amphetamine-like stimulants. Rather, modafinil may act by stimulating α -adrenoceptors, suppressing GABA release, weakly inhibiting the dopamine transporter, or stimulating hypothalamic orexin-containing neurons (Ballon and Feifel, 2006; Martinez-Raga *et al.*, 2008). Other mechanisms of action that have been reported include reductions in circulating free radicals and cytotoxicity induced by sleep deprivation (Gerrard and Malcolm, 2007). While most studies suggest a dopaminergic basis for its stimulant effects (Andersen *et al.*, 2010; Volkow *et al.*, 2009; Wisor and Eriksson, 2005), modafinil has been shown to elevate extracellular levels of glutamate in numerous brain regions including the dorsal striatum, hippocampus and diencephalon (see Figure 1) (Ferraro *et al.*, 1997, 1998, 1999) without affecting glutamate synthesis (Perez de la Mora *et al.*, 1999). Modafinil is considered to have low abuse potential (Martinez-Raga *et al.*, 2008), although reports of abuse potential at high doses (Andersen *et al.*, 2010) and non-medical use are increasing (Ballon and Feifel, 2006). As a result modafinil is currently classified as a Schedule IV controlled substance by the Drug Enforcement Administration. Clinically effective doses of modafinil are typically in the range of 200–400 mg/day.

2.7.2. Clinical Efficacy—Numerous clinical reports have shown that modafinil demonstrates potential efficacy in the treatment of cocaine addiction (Martinez-Raga *et al.*, 2008). In a small placebo-controlled drug-interaction study by Dackis and colleagues, it was reported that modafinil (200 mg/day) blunted the euphorogenic effects of intravenous cocaine in cocaine addicts (Dackis *et al.*, 2003), and these findings were later independently replicated (Malcolm *et al.*, 2006). A double-blind placebo-controlled study of treatment-seeking cocaine-dependent outpatients showed that modafinil (400 mg/day) significantly reduced daily cocaine use and prolonged abstinence (Dackis *et al.*, 2005). A recent multi-center clinical trial found that modafinil decreased cocaine use and craving in cocaine-dependent subjects without co-morbid alcohol dependence (Anderson *et al.*, 2009). Although these data demonstrate that modafinil might be of use in the treatment of cocaine addiction, it is possible that some of the beneficial effects might be due to decreases in peak plasma concentrations of cocaine in the presence of modafinil (Donovan *et al.*, 2005). Modafinil has also produced nonsignificant trends towards decreases in active methamphetamine use amongst abusers of this drug (Shearer *et al.*, 2009), and reductions in gambling behaviors in impulsive problematic gamblers (Zack and Poulos, 2009). Despite these positive results indicating a potential for modafinil in treating psychostimulant addicts

and pathological gamblers, a recent study indicated that modafinil is ineffective in reducing cigarette smoking and actually produces more signs of withdrawal and negative affect than in placebo treated smokers (Schnoll *et al.*, 2008). Thus, modafinil does not appear to be well suited for use in the treatment of smoking cessation.

From a neurochemical viewpoint, it is somewhat confusing as to why a drug like modafinil, which increases extracellular glutamate levels, results in reductions in cocaine intake, in light of numerous animal studies have shown that blockade of glutamatergic neurotransmission (i.e., by administration of ionotropic glutamate receptor antagonists, postsynaptic mGluR antagonists, or presynaptic mGluR2/3 agonists that suppress glutamate release) reduces cocaine reinforcement and/or reinstatement of cocaine-seeking behavior (Gass and Olive, 2008; Kalivas *et al.*, 2009; Knackstedt and Kalivas, 2009; Olive, 2009; Tzschentke and Schmidt, 2003). One possible hypothesis for the mechanism of action of modafinil in reducing cocaine craving is by normalizing the reductions in extracellular glutamate that are observed in the nucleus accumbens during cocaine withdrawal, and attenuate the ability of cocaine or cocaine-related cues to evoke craving (similar to the hypothesized mechanism of action for NAC - Figure 1). Further studies are needed to test this hypothesis.

2.8. Topiramate

2.8.1. Mechanism of Action—Topiramate, like other anticonvulsants including gabapentin and lamotrigine, has multiple mechanisms of action, including inhibition of presynaptic voltage-gated Na⁺ and Ca²⁺ channels (thereby inhibiting the release of neurotransmitters including glutamate) and activation of type A GABA (GABA_A) receptors (Dickenson and Ghandehari, 2007; Landmark, 2007; Rogawski and Loscher, 2004). In addition, it has recently been shown that topiramate is also an antagonist at α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors containing the GluR5 subunit (Figure 1) (Gryder and Rogawski, 2003; Kaminski *et al.*, 2004). These actions on AMPA receptor function are of particular interest since this glutamate receptor subtype has been highly indicated in the neuroadaptive changes produced by drugs of abuse as well as mediating drug self-administration and relapse-like behaviors (Bowers *et al.*, 2010; Gass and Olive, 2008; Niehaus *et al.*, 2009; Xi and Gardner, 2008). Typical effective doses of topiramate range from 75–350 mg/day.

2.8.2. Clinical Efficacy—In addition to the attenuation of alcohol withdrawal symptoms similar to that observed with gabapentin and lamotrigine (Krupitsky *et al.*, 2007b), topiramate may also aid in the amelioration of benzodiazepine withdrawal symptoms (Michopoulos *et al.*, 2006). Numerous studies have been published in the last decade demonstrating efficacy of topiramate in attenuating alcohol's subjective effects, alcohol craving, and heavy consumption in alcoholic patients (Anderson and Oliver, 2003; Johnson *et al.*, 2004; Kenna *et al.*, 2009; Komanduri, 2003; Ma *et al.*, 2006; Miranda *et al.*, 2008; Rubio *et al.*, 2004). The ability of topiramate to reduce compulsive drinking may be due to its ability to modulate impulsivity and improve behavioral inhibition (Rubio *et al.*, 2009). One study even found indications that topiramate was superior to the “gold standard” anti-alcoholism medication naltrexone in prolonging abstinence and reducing on-going drinking and relapse (Baltieri *et al.*, 2008). Thus, topiramate appears to be a promising medication for use in the treatment of alcoholism.

With regards to other drugs of abuse, topiramate has been shown to reduce cocaine use and craving in cocaine-dependent individuals (Kampman *et al.*, 2004; Reis *et al.*, 2008), yet the small sample sizes of these two clinical studies are limiting (Minozzi *et al.*, 2008). A case report indicated that topiramate reduces the use of methylenedioxymethamphetamine

(MDMA, “Ecstasy”) (Akhondzadeh and Hampa, 2005). In cigarette smokers, some small studies have shown beneficial effects of topiramate in promoting abstinence from smoking or reducing overall smoking behavior (Arbaizar *et al.*, 2008; Johnson *et al.*, 2005; Khazaal *et al.*, 2006). The ability of topiramate to prolong abstinence from smoking may be gender-specific, with great responses in males (Anthenelli *et al.*, 2008). However, one study found that, similar to lamotrigine, topiramate increased the subjective effects of withdrawal from smoking as well as the rewarding effects of a smoked cigarette and did not affect cue-induced craving (Reid *et al.*, 2007), questioning the potential use of topiramate as an aid in smoking cessation. Similarly, topiramate has been shown to enhance the subjective positive feelings produced by methamphetamine (Johnson *et al.*, 2007). Thus, topiramate may hold promise for aiding in the treatment of addiction to alcohol and possibly cocaine and nicotine, but more studies are needed to examine its potential as a therapeutic for treating addiction to other drugs of abuse.

With regards to behavioral addictions, a handful of small studies and case reports have been published in recent years indicating that topiramate may also be of potential use in the treatment of these disorders. Thus far, positive effects of topiramate have been observed in reducing relapse to problematic gambling (Dannon *et al.*, 2007) and reducing compulsive eating and sexual behavior (Fong *et al.*, 2005; Khazaal and Zullino, 2006; Tata and Kockler, 2006). Clearly this avenue for treatment of non-drug addictions needs to be explored further.

3. Summary and Conclusions

With regards to the eight medications reviewed here that possess a glutamatergic mechanism of action (acamprosate, NAC, DCS, gabapentin, lamotrigine, memantine, modafinil, and topiramate), we conclude that NAC, modafinil, and topiramate have the most well-documented and greatest potential for use in the treatment of drug and behavioral addictions. Certainly any of the medications reviewed here will not be a panacea for all addictions, but more likely an effective pharmacological aid to standard individual psychotherapy or cognitive-behavioral therapy approaches for treating addiction to certain drugs of abuse (particularly cocaine and alcohol) as well as non-drug addictions (particularly pathological gambling). Combined with standard retrospective or outcome measure-based attempts at identifying subtypes of individual addicts that may respond more favorably to one medication or another, with the fewest adverse side effects, the post-genomic era of today will hopefully allow researchers and clinicians to utilize pharmacogenetic approaches to identifying potential responders and non-responders to each of these medications prior to initiating treatment. The limited amount of data available for some of these compounds, such as DCS and lamotrigine, warrants larger scale multi-center studies. In addition, increased investigation with appropriate animal models into the precise glutamatergic mechanisms that mediate different aspects of the addiction cycle (i.e., compulsive drug use, withdrawal, craving, drug-seeking behavior, and relapse) will hopefully lead to more effective pharmacological approaches that can be used to intervene at specific stages of addiction.

Acknowledgments

The authors would like to thank Katie Ris-Vicari for assistance with the generation of the artwork. This work was supported by NIH grants DA024355, DA025606, and AA013852 (MFO).

References

- Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. *Brain Res.* 2004; 1029:41–47. [PubMed: 15533314]

- Akhondzadeh S, Hampa AD. Topiramate prevents ecstasy consumption: a case report. *Fundam Clin Pharmacol*. 2005; 19:601–602. [PubMed: 16176341]
- al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. *Alcohol Clin Exp Res*. 1998; 22:810–814. [PubMed: 9660305]
- Amen SL, Piacentini LB, Ahmad ME, Li S-J, Mantsch JR, Risinger RC, et al. Repeated N-acetylcysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. *Neuropsychopharmacology*. 2011; 36:871–878. [PubMed: 21160464]
- Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL. Dopamine transporter-related effects of modafinil in rhesus monkeys. *Psychopharmacology*. 2010; 210:439–448. [PubMed: 20386883]
- Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. *Drug Alcohol Depend*. 2009; 104:133–139. [PubMed: 19560290]
- Anderson N, Oliver MN. Oral topiramate effective for alcoholism. *J Fam Pract*. 2003; 52:682–683. 7. [PubMed: 12967537]
- Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. *Addiction*. 2008; 103:687–694. [PubMed: 18339115]
- Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence - the COMBINE study: a randomized controlled trial. *JAMA*. 2006; 295:2003–2017. [PubMed: 16670409]
- Arbaizar B, Gomez-Acebo I, Llorca J. Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report. *J Med Case Rep*. 2008; 2:198.
- Arias AJ, Feinn R, Covault J, Kranzler HR. Memantine for alcohol dependence: an open-label pilot study. *Addict Disord Treat*. 2007; 6:77–83.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th Edition. Washington DC: American Psychiatric Press; 2002. Text Revision. 4th, Text Revision ed.
- Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci*. 2003; 6:743–749. [PubMed: 12778052]
- Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. *J Neurosci*. 2002; 22:9134–9141. [PubMed: 12388621]
- Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. *J Clin Psychiatry*. 2006; 67:554–566. [PubMed: 16669720]
- Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. *Addiction*. 2008; 103:2035–2044. [PubMed: 18855810]
- Berger SP, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. *Addiction*. 2005; 100 Suppl 1:58–67. [PubMed: 15730350]
- Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. *CNS Spectr*. 2009; 14:357–360. [PubMed: 19773711]
- Berton F, Francesconi WG, Madamba SG, Zieglgänsberger W, Siggins GR. Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA_B receptors in nucleus accumbens neurons. *Alcohol Clin Exp Res*. 1998; 22:183–191. [PubMed: 9514305]
- Bird MK, Lawrence AJ. Group I metabotropic glutamate receptors: involvement in drug-seeking and drug-induced plasticity. *Curr Mol Pharmacol*. 2009; 2:83–94. [PubMed: 20021449]
- Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. *Drug Alcohol Depend*. 2006; 81:267–274. [PubMed: 16169160]
- Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. *Psychopharmacology*. 2001; 157:1–10. [PubMed: 11512037]
- Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. *Psychopharmacology*. 2004; 172:16–24. [PubMed: 14530901]

- Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. *Drug Alcohol Depend.* 2006; 83:25–32. [PubMed: 16298087]
- Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. *Pharmacopsychiatry.* 1999; 32:107–109. [PubMed: 10463378]
- Botreau F, Paolone G, Stewart J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. *Behav Brain Res.* 2006; 172:173–178. [PubMed: 16769132]
- Bowers MS, Chen BT, Bonci A. AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future. *Neuron.* 2010; 67:11–24. [PubMed: 20624588]
- Bowers MS, Chen BT, Chou JK, Osborne MPH, Gass JT, See RE, et al. Acamprosate attenuates cocaine and cue-induced reinstatement of cocaine-seeking behavior in rats. *Psychopharmacology.* 2007; 195:397–406. [PubMed: 17764007]
- Bozikas V, Petrikis P, Gamvrla K, Savvidou I, Karavatos A. Treatment of alcohol withdrawal with gabapentin. *Prog Neuropsychopharmacol Biol Psychiatry.* 2002; 26:197–199. [PubMed: 11853112]
- Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. *Alcohol Clin Exp Res.* 2008; 32:1429–1438. [PubMed: 18540923]
- Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. *J Clin Psychiatry.* 2003; 64:197–201. [PubMed: 12633129]
- Brown ES, Perantie DC, Dhanani N, Beard L, Orsulak P, Rush AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. *J Affect Disord.* 2006; 93:219–222. [PubMed: 16519947]
- Cartwright WS. Economic costs of drug abuse: financial, cost of illness, and services. *J Subst Abuse Treat.* 2008; 34:224–233. [PubMed: 17596904]
- Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. *J Neurochem.* 2007; 100:1289–1299. [PubMed: 17241130]
- Collins ED, Vosberg SK, Ward AS, Haney M, Foltin RW. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. *Exp Clin Psychopharmacol.* 2007; 15:228–237. [PubMed: 17563209]
- Collins ED, Ward AS, McDowell DM, Foltin RW, Fischman MW. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. *Behav Pharmacol.* 1998; 9:587–598. [PubMed: 9862084]
- Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. *Psychopharmacology.* 2007; 193:235–245. [PubMed: 17406858]
- Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. *Neuropharmacology.* 2000; 39:2139–2146. [PubMed: 10963757]
- Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. *Eur J Neurosci.* 2004; 20:1566–1576. [PubMed: 15355323]
- Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. *Neuropsychopharmacology.* 2005; 30:205–211. [PubMed: 15525998]
- Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. *Drug Alcohol Depend.* 2003; 70:29–37. [PubMed: 12681523]
- Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. *J Clin Psychopharmacol.* 2007; 27:620–624. [PubMed: 18004130]
- Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. *Biol Psychiatry.* 2006; 60:369–375. [PubMed: 16919524]

- De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate : elucidating the mechanism of action. *CNS Drugs*. 2005; 19:517–537. [PubMed: 15963001]
- Dickenson AH, Ghandehari J. Anti-convulsants and anti-depressants. *Handb Exp Pharmacol*. 2007:145–177. [PubMed: 17087123]
- Donovan DM, Anton RF, Miller WR, Longabaugh R, Hosking JD, Youngblood M. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. *J Stud Alcohol Drugs*. 2008; 69:5–13. [PubMed: 18080059]
- Donovan JL, DeVane CL, Malcolm RJ, Mojsiak J, Chiang CN, Elkashef A, et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. *Clin Pharmacokinet*. 2005; 44:753–765. [PubMed: 15966757]
- Dooley DJ, Mieske CA, Borosky SA. Inhibition of K⁺-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. *Neurosci Lett*. 2000; 280:107–110. [PubMed: 10686389]
- Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. *Alcohol Clin Exp Res*. 2007; 31:775–782. [PubMed: 17378918]
- Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcotic drug modafinil increases glutamate release in thalamic areas and hippocampus. *NeuroReport*. 1997; 8:2883–2887. [PubMed: 9376524]
- Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. *Neurosci Lett*. 1998; 253:135–138. [PubMed: 9774168]
- Ferraro L, Antonelli T, Tanganelli S, O'Connor WT, Perez de la Mora M, Mendez-Franco J, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABA_A receptor blockade. *Neuropsychopharmacology*. 1999; 20:346–356. [PubMed: 10088135]
- Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca²⁺ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. *Br J Pharmacol*. 2000; 130:900–906. [PubMed: 10864898]
- Fong TW, De La Garza R 2nd, Newton TF. A case report of topiramate in the treatment of nonparaphilic sexual addiction. *J Clin Psychopharmacol*. 2005; 25:512–514. [PubMed: 16160641]
- Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2007; 68:1691–1700. [PubMed: 18052562]
- Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. *Biochem Pharmacol*. 2008; 75:218–265. [PubMed: 17706608]
- Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. *Neuropsychiatr Dis Treat*. 2007; 3:349–364. [PubMed: 19300566]
- Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. *Pain Med*. 2009; 10 Suppl 2:S89–S100. [PubMed: 19691688]
- Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. *Drug Alcohol Depend*. 2007; 87:1–9. [PubMed: 16930857]
- Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. *Psychopharmacology*. 2010b; 212:603–612. [PubMed: 20721537]
- Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. *Biol Psychiatry*. 2007; 62:652–657. [PubMed: 17445781]
- Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. *Arch Gen Psychiatry*. 2009; 66:756–763. [PubMed: 19581567]
- Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. *Am J Drug Alcohol Abuse*. 2010a; 36:233–241. [PubMed: 20560821]

- Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. *Am J Addict*. 2010; 19:187–189. [PubMed: 20163391]
- Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. *J Neurosci*. 2003; 23:7069–7074. [PubMed: 12904467]
- Haney M, Hart C, Collins ED, Foltin RW. Smoked cocaine discrimination in humans: effects of gabapentin. *Drug Alcohol Depend*. 2005; 80:53–61. [PubMed: 16157231]
- Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, et al. Acamprosate inhibits the binding of neurotoxic effects on trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. *Alcohol Clin Exp Res*. 2002; 26:1779–1793. [PubMed: 12500101]
- Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. *Drug Alcohol Depend*. 2006; 85:177–184. [PubMed: 16740370]
- Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. *Neuropsychopharmacology*. 2009; 34:257–265. [PubMed: 18418361]
- Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. *Arch Intern Med*. 2005; 165:1600–1605. [PubMed: 16043677]
- Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. *Arch Gen Psychiatry*. 2004; 61:905–912. [PubMed: 15351769]
- Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, et al. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. *Int J Neuropsychopharmacol*. 2007; 10:85–98. [PubMed: 16448579]
- Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. *Neuropharmacology*. 2009; 56 Suppl:169–173. [PubMed: 18675832]
- Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. *Neuropharmacology*. 2004; 46:1097–1104. [PubMed: 15111016]
- Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. *Addict Behav*. 2011; 36:217–221. [PubMed: 21112155]
- Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. *Drug Alcohol Depend*. 2004; 75:233–240. [PubMed: 15283944]
- Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. *Addict Behav*. 2009; 34:581–586. [PubMed: 19345510]
- Kau KS, Madayag A, Mantsch JR, Grier MD, Abdulhameed O, Baker DA. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. *Neuroscience*. 2008; 155:530–537. [PubMed: 18601982]
- Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. *Curr Drug Abuse Rev*. 2009; 2:135–142. [PubMed: 19630744]
- Kennedy WK, Leloux M, Kutscher EC, Price PL, Morstad AE, Carnahan RM. Acamprosate. *Expert Opin Drug Metab Toxicol*. 2010; 6:363–380. [PubMed: 20163323]
- Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. *Psychiatry Clin Neurosci*. 2006; 60:384–388. [PubMed: 16732758]
- Khazaal Y, Zullino DF. Topiramate in the treatment of compulsive sexual behavior: case report. *BMC Psychiatry*. 2006; 6:22. [PubMed: 16719909]

- Kheirabadi GR, Ranjkesh M, Maracy MR, Salehi M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. *Addiction*. 2008; 103:1495–1499. [PubMed: 18783503]
- Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. *Curr Pharm Des*. 2010; 16:2098–2102. [PubMed: 20482510]
- Knackstedt LA, Kalivas PW. Glutamate and reinstatement. *Curr Opin Pharmacol*. 2009; 9:59–64. [PubMed: 19157986]
- Knackstedt LA, Larowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. *Biol Psychiatry*. 2009; 65:841–845. [PubMed: 19103434]
- Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. *Biol Psychiatry*. 2010; 67:81–84. [PubMed: 19717140]
- Komanduri R. Two cases of alcohol craving curbed by topiramate. *J Clin Psychiatry*. 2003; 64:612. [PubMed: 12755670]
- Koob GF, Kenneth Lloyd G, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. *Nat Rev Drug Discov*. 2009; 8:500–515. [PubMed: 19483710]
- Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. *Am J Addict*. 2008; 17:70–76. [PubMed: 18214726]
- Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. *Am J Psychiatry*. 2007a; 164:519–523. [PubMed: 17329479]
- Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. *Alcohol Clin Exp Res*. 2007b; 31:604–611. [PubMed: 17374039]
- Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. *Alcohol Alcohol*. 2008; 43:53–61. [PubMed: 17965444]
- Landmark CJ. Targets for antiepileptic drugs in the synapse. *Med Sci Monit*. 2007; 13:RA1–RA7. [PubMed: 17179916]
- LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas PW, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. *Am J Addict*. 2006; 15:105–110. [PubMed: 16449100]
- LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine? *Am J Psychiatry*. 2007; 164:1115–1117. [PubMed: 17606664]
- Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. *Epilepsia*. 1986; 27:490–497. [PubMed: 3757936]
- Lee JL, Gardner RJ, Butler VJ, Everitt BJ. D-cycloserine potentiates the reconsolidation of cocaine-associated memories. *Learn Mem*. 2009; 16:82–85. [PubMed: 19144966]
- Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. *Brain Res*. 1993; 612:190–199. [PubMed: 7687190]
- Lejoyeux M, Leher P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. *Alcohol Alcohol*. 2011; 46:61–67. [PubMed: 21118900]
- Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. *Lancet*. 1985; 1(8436): 1014–1016. [PubMed: 2859465]
- Lingamaneni R, Hemmings HC Jr. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. *Neurosci Lett*. 1999; 276:127–130. [PubMed: 10624808]

- LoCastro JS, Youngblood M, Cisler RA, Mattson ME, Zweben A, Anton RF, et al. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. *J Stud Alcohol Drugs*. 2009; 70:186–196. [PubMed: 19261230]
- Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. *Addiction*. 2006; 101:1561–1568. [PubMed: 17034435]
- Madamba SG, Schweitzer P, Zieglgänsberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. *Alcohol Clin Exp Res*. 1996; 20:651–658. [PubMed: 8800380]
- Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. *J Neurosci*. 2007; 27:13968–13976. [PubMed: 18094234]
- Malcolm R, Myrick LH, Veatch LM, Boyle E, Randall PK. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. *J Clin Sleep Med*. 2007; 3:24–32. [PubMed: 17557449]
- Malcolm R, Swayngim K, Donovan JL, DeVane CL, Elkashef A, Chiang N, et al. Modafinil and cocaine interactions. *Am J Drug Alcohol Abuse*. 2006; 32:577–587. [PubMed: 17127546]
- Malliarakis KD, Lucey P. Social determinates of health: focus on substance use and abuse. *Nurs Econ*. 2007; 25:368–370. 75. [PubMed: 18240840]
- Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by gabapentin of K⁺-evoked release of [³H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. *Br J Pharmacol*. 2004; 141:574–579. [PubMed: 14744819]
- Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. *Br J Pharmacol*. 2001; 134:237–240. [PubMed: 11564640]
- Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. *Alcohol Clin Exp Res*. 2008; 32:1105–1110. [PubMed: 18540918]
- Mardikian PN, Larowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007; 31:389–394. [PubMed: 17113207]
- Margolin A, Avants SK, DePhilippis D, Kosten TR. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. *Am J Drug Alcohol Abuse*. 1998; 24:85–101. [PubMed: 9513631]
- Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. *Am J Addict*. 2006; 15:76–84. [PubMed: 16449096]
- Martinez-Raga J, Knecht C, Cepeda S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. *Curr Drug Abuse Rev*. 2008; 1:213–221. [PubMed: 19630720]
- Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004; 28:599–601. [PubMed: 15093968]
- Mason BJ, Goodman AM, Chabac S, Leher P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. *J Psychiatr Res*. 2006; 40:383–393. [PubMed: 16546214]
- Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. *CNS Neurol Disord Drug Targets*. 2010a; 9:23–32. [PubMed: 20201812]
- Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. *Expert Opin Drug Saf*. 2010b; 9:177–188. [PubMed: 20021295]
- Mason BJ, Leher P. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. *Am J Addict*. 2010; 19:147–154. [PubMed: 20163387]

- Mason BJ, Light JM, Williams LD, Drobos DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. *Addict Biol.* 2009; 14:73–83. [PubMed: 18855801]
- McBean GJ. Cerebral cystine uptake: a tale of two transporters. *Trends Pharmacol Sci.* 2002; 23:299–302. [PubMed: 12119142]
- Mcgeehan AJ, Olive MF. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. *Br J Pharmacol.* 2003; 138:9–12. [PubMed: 12522067]
- Mcgeehan AJ, Olive MF. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. *Behav Pharmacol.* 2006; 17:363–367. [PubMed: 16914955]
- Melendez RI, Vuthiganon J, Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. *J Pharmacol Exp Ther.* 2005; 314:139–147. [PubMed: 15769865]
- Michopoulos I, Douzenis A, Christodoulou C, Lykouras L. Topiramate use in alprazolam addiction. *World J Biol Psychiatry.* 2006; 7:265–267. [PubMed: 17071548]
- Minozzi S, Amato L, Davoli M, Farrell M, Lima Reisser AA, Pani PP, et al. Anticonvulsants for cocaine dependence. *Cochrane Database Syst Rev.* 2008 CD006754.
- Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. *Alcohol Clin Exp Res.* 2008; 32:489–497. [PubMed: 18215213]
- Montoya ID, Vocci F. Novel medications to treat addictive disorders. *Curr Psychiatry Rep.* 2008; 10:392–398. [PubMed: 18803912]
- Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. *J Neurosci.* 2005; 25:6389–6393. [PubMed: 16000629]
- Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. *Addiction.* 2006; 101:1451–1462. [PubMed: 16968347]
- Moussawi K, Kalivas PW. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. *Eur J Pharmacol.* 2010; 639:115–122. [PubMed: 20371233]
- Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. *Nat Neurosci.* 2009; 12:182–189. [PubMed: 19136971]
- Myers KM, Carlezon WA Jr, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. *Neuropsychopharmacology.* 2011; 36:274–293. [PubMed: 20631689]
- Myers KM, Davis M. Mechanisms of fear extinction. *Mol Psychiatry.* 2007; 12:120–150. [PubMed: 17160066]
- Myrick H, Anton R, Voronin K, Wang W, Henderson S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. *Alcohol Clin Exp Res.* 2007; 31:221–227. [PubMed: 17250613]
- Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. *J Clin Psychiatry.* 2001; 62:19–23. [PubMed: 11235923]
- Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. *Am J Psychiatry.* 1998; 155:1632. [PubMed: 9812141]
- Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. *Alcohol Clin Exp Res.* 2009; 33:1582–1588. [PubMed: 19485969]
- Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. *Alcohol Clin Exp Res.* 1998; 22:802–809. [PubMed: 9660304]
- Nic Dhonnchadha BA, Szalay JJ, Achat-Mendes C, Platt DM, Otto MW, Speelman RD, et al. D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. *Neuropsychopharmacology.* 2010; 35:357–367. [PubMed: 19741593]

- Niehaus JL, Cruz-Bermudez ND, Kauer JA. Plasticity of addiction: a mesolimbic dopamine short-circuit? *Am J Addict*. 2009; 18:259–271. [PubMed: 19444729]
- O'Brien CP. Evidence-based treatments of addiction. *Philos Trans R Soc Lond B Biol Sci*. 2008; 363:3277–3286. [PubMed: 18640914]
- Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for drug addiction. *Curr Drug Abuse Rev*. 2009; 2:83–98. [PubMed: 19630739]
- Olive MF. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. *Eur J Pharmacol*. 2010; 639:47–58. [PubMed: 20371237]
- Pavlovic Z. Lamotrigine reduces craving and depressive symptoms in cocaine dependence. *J Neuropsychiatry Clin Neurosci*. 2011; 23:E32. [PubMed: 21304126]
- Perez de la Mora M, Aguilar-Garcia A, Ramon-Frias T, Ramirez-Ramirez R, Mendez-Franco J, Rambert F, et al. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. *Neurosci Lett*. 1999; 259:181–185. [PubMed: 10025588]
- Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. *Eur J Pharmacol*. 2000; 394:221–231. [PubMed: 10771287]
- Price KL, McRae-Clark AL, Saladin ME, Maria MM, DeSantis SM, Back SE, et al. D-cycloserine and cocaine cue reactivity: preliminary findings. *Am J Drug Alcohol Abuse*. 2009; 35:434–438. [PubMed: 20014913]
- Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The novel anti-craving drug acamprosate alters the expression of NMDA1 receptor splice variant mRNAs in the rat brain. *J Neural Transm*. 1996; 103:XLV–XLVI.
- Raby WN. Gabapentin therapy for cocaine cravings. *Am J Psychiatry*. 2000; 157:2058–2059. [PubMed: 11097986]
- Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. *J Clin Psychiatry*. 2004; 65:84–86. [PubMed: 14744174]
- Raj YP. Gambling on acamprosate: a case report. *J Clin Psychiatry*. 2010; 71:1245–1246. [PubMed: 20923626]
- Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. *Neuropharmacology*. 2001; 40:749–760. [PubMed: 11369029]
- Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. *Lancet*. 2009; 373:2223–2233. [PubMed: 19560604]
- Reid MS, Palamar J, Raghavan S, Flammio F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. *Psychopharmacology*. 2007; 192:147–158. [PubMed: 17345064]
- Reilly MT, Lobo IA, McCracken LM, Borghese CM, Gong D, Horishita T, et al. Effects of acamprosate on neuronal receptors and ion channels expressed in *Xenopus* oocytes. *Alcohol Clin Exp Res*. 2008; 32:188–196. [PubMed: 18226119]
- Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. *Rev Bras Psiquiatr*. 2008; 30:132–135. [PubMed: 18470406]
- Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. *Behav Pharmacol*. 2010; 21:514–522. [PubMed: 20634691]
- Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? *Addiction*. 2008; 103:953–959. [PubMed: 18482418]
- Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*. 2004; 5:553–564. [PubMed: 15208697]
- Rosner S, Hackl-Herrwerth A, Leucht S, Leher P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. *Cochrane Database Syst Rev*. 2010 CD004332.

- Ross S, Peselow E. Pharmacotherapy of addictive disorders. *Clin Neuropharmacol*. 2009; 32:277–289. [PubMed: 19834993]
- Rubio G, Lopez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. *Bipolar Disord*. 2006; 8:289–293. [PubMed: 16696832]
- Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. *J Clin Psychopharmacol*. 2009; 29:584–589. [PubMed: 19910725]
- Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. *Pharmacopsychiatry*. 2004; 37:37–40. [PubMed: 14750047]
- Rustembegovic A, Sofic E, Tahirovic I, Kundurovic Z. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. *Med Arh*. 2004; 58:5–6. [PubMed: 15017894]
- Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. *Drug Alcohol Depend*. 2009; 104:220–227. [PubMed: 19592176]
- Sari Y, Smith KD, Ali PK, Rebec GV. Upregulation of Glt1 attenuates cue-induced reinstatement of cocaine-seeking behavior. *J Neurosci*. 2009; 29:9239–9243. [PubMed: 19625514]
- Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, et al. A placebo-controlled trial of modafinil for nicotine dependence. *Drug Alcohol Depend*. 2008; 98:86–93. [PubMed: 18541389]
- Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. *Addiction*. 2009; 104:224–233. [PubMed: 19149817]
- Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. *Neuropharmacology*. 2001; 41:151–158. [PubMed: 11489451]
- Shen YC. Treatment of inhalant dependence with lamotrigine. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 31:769–771. [PubMed: 17254687]
- Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. *Pain*. 2000; 85:405–414. [PubMed: 10781913]
- Sitges M, Chiu LM, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na⁺ channel-mediated release of [³H]glutamate in hippocampal nerve endings. *Neuropharmacology*. 2007; 52:598–605. [PubMed: 17070874]
- Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. *Am J Drug Alcohol Abuse*. 2008; 34:449–461. [PubMed: 18584575]
- Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. *Physiol Rev*. 2009; 89:649–705. [PubMed: 19342616]
- Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, et al. The clock gene *Per2* influences the glutamatergic system and modulates alcohol consumption. *Nat Med*. 2005; 11:35–42. [PubMed: 15608650]
- Tata AL, Kockler DR. Topiramate for binge-eating disorder associated with obesity. *Ann Pharmacother*. 2006; 40:1993–1997. [PubMed: 17047134]
- Teoh H, Fowler LJ, Bowery NG. Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. *Neuropharmacology*. 1995; 34:1273–1278. [PubMed: 8570024]
- Thanos PK, Bermeo C, Wang GJ, Volkow ND. D-Cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57BL/c mice. *Behav Brain Res*. 2009; 199:345–349. [PubMed: 19152811]
- Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Chaikledkaew U. The economic impact of alcohol consumption: a systematic review. *Subst Abuse Treat Prev Policy*. 2009; 4:20. [PubMed: 19939238]
- Torregrassa MM, Sanchez H, Taylor JR. D-cycloserine reduces the context specificity of Pavlovian extinction of cocaine cues through actions in the nucleus accumbens. *J Neurosci*. 2010; 30:10526–10533. [PubMed: 20685995]
- Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. *Mol Psychiatry*. 2003; 8:373–382. [PubMed: 12740594]

- Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. *Arch Gen Psychiatry*. 2010; 67:1069–1077. [PubMed: 20921123]
- Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. *CNS Neurol Disord Drug Targets*. 2008; 7:482–491. [PubMed: 19128205]
- Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. *JAMA*. 2009; 301:1148–1154. [PubMed: 19293415]
- Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ. Gabapentin for the treatment of ethanol withdrawal. *Subst Abus*. 2003; 24:129–132. [PubMed: 12766380]
- Vosburg SK, Hart CL, Haney M, Foltin RW. An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. *Drug Alcohol Depend*. 2005; 79:257–260. [PubMed: 16002035]
- Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. *Neurology*. 1995; 45:1907–1913. [PubMed: 7477991]
- Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. *Naunyn Schmied Arch Pharmacol*. 1996; 354:164–172.
- Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. *Neuroreport*. 2001; 12:2255–2258. [PubMed: 11447345]
- Weiss RD, O'Malley SS, Hosking JD, Locastro JS, Swift R. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. *J Stud Alcohol Drugs*. 2008; 69:878–884. [PubMed: 18925346]
- White WD, Crockford D, Patten S, El-Guebaly N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. *Nicotine Tob Res*. 2005; 7:809–813. [PubMed: 16191752]
- Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, et al. Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects. *Am J Drug Alcohol Abuse*. 2000; 26:47–59. [PubMed: 10718163]
- Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. *Neuroscience*. 2005; 132:1027–1034. [PubMed: 15857707]
- Xi ZX, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. *Curr Drug Abuse Rev*. 2008; 1:303–327. [PubMed: 19430578]
- Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. *J Psychopharmacol*. 2009; 23:660–671. [PubMed: 18583430]
- Zahm DS. Pharmacotherapeutic approach to the treatment of addiction: persistent challenges. *Mol Med*. 2010; 107:276–280.
- Zeise ML, Kasparov S, Capogna M, Zieglgänsberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. *Eur J Pharmacol*. 1993; 231:47–52. [PubMed: 8444281]
- Zeise ML, Kasparow S, Capogna M, Zieglgänsberger W. Calcium diacetylhomotaurinate (CA-AOTA) decreases the action of excitatory amino acids in the rat neocortex in vitro. *Prog Clin Biol Res*. 1990; 351:237–242. [PubMed: 2236130]

Figure 1.

Putative glutamatergic mechanisms of action of 8 anti-addiction medications. *Acamprosate* - The molecular target(s) of acamprosate is still uncertain, but several studies have indicated it modulates the activity of NMDA receptors and restores balance between excitatory and inhibitory neurotransmission that is altered by chronic alcohol consumption. *N-acetylcysteine (NAC)* is a cystine prodrug that stimulates the cystine-glutamate exchanger (xc-) on glia to normalize extracellular levels of glutamate, which are reduced in the nucleus accumbens during cocaine withdrawal. This normalization of extracellular glutamate levels restores glutamatergic tone on release-inhibiting presynaptic mGluR2/3 receptors, which in turn inhibits the ability of exposure to cocaine (and perhaps cocaine-associated cues) to elevate extracellular glutamate and evoke cocaine craving or relapse. *D-cycloserine (DCS)* is a partial agonist at the glycine co-agonist binding site on NR1 subunits that are intrinsic to all NMDA receptors, and thus DCS potentiates cation influx through the NMDA receptor complex. *Modafinil* has numerous actions on neurons and its precise molecular targets have yet to be identified. However, several microdialysis studies have shown that modafinil increases extracellular levels of glutamate in various brain regions. *Gabapentin, lamotrigine, topiramate* are anticonvulsants that have numerous mechanisms of action, one of which is the reduction of the release of glutamate by blocking cation influx through presynaptic Na⁺ and Ca²⁺ channels. Topiramate has the unique ability to also antagonize GluR5-containing AMPA receptors. *Memantine* is a non-competitive NMDA receptor antagonist.